Endpoints News 生物医药· Lei Lei Wu·· 2026-10-06精选AI 评分67
ArriVent肺癌药firmonertinib III期试验失败,公司股价大跌
ArriVent's lung cancer drug firmonertinib fails key late-stage trial, stock tanks
AI 导读
ArriVent BioPharma报告其主打肺癌药物firmonertinib在III期临床试验中失败,公司股价随之大跌。
推荐理由
III期失败直接冲击ArriVent核心管线估值,该结果对肺癌靶向药竞争格局、企业估值与投资判断均具有参考价值。
正文 · 原文
ArriVent BioPharma, an early adopter of the China licensing model, reported that its lead lung cancer drug failed a Phase 3 trial.
Firmonertinib, an EGFR …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news